Duvuru Geetha1, Scott M Lee2, Shivani Shah3, Hafizur M Rahman4. 1. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. gduvura@jhmi.edu. 2. Baylor University and Baylor College of Medicine's Baylor² Medical Track, Waco, TX, USA. 3. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 4. Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
BACKGROUND: Renal transplantation (RTx) is the modality of choice for ESRD due to ANCA associated vasculitis (AAV). The significance of ANCA positivity (ANCA+) at the time of RTx on recurrent disease is controversial. METHODS: We evaluated clinical outcomes and predictors of vasculitis relapse in sixteen transplanted AAV patients who were ANCA+ at RTx at a single University Medical Center. Allograft function, vasculitis relapse, and predictors of vasculitis relapse were assessed using descriptive statistics and logistic regression analysis. RESULTS: Our cohort had a median age of 64 years, 88 % Caucasians, 63 % males, 50 % PR3+. All patients were in remission at the time of RTx. Twelve received induction therapy and all were on mycophenolate mofetil, prednisone and tacrolimus. The mean (SD) serum creatinine was 1.2 (0.3) mg/dl at 1 year and 1.8 (1.7) mg/dl at last follow up. Six developed vasculitis relapse at post-transplant. All relapses were treated with escalation in immunosuppression. One non-compliant patient suffered graft loss while the remaining patients achieved remission. In adjusted logistic regression analysis, PR3 ANCA+ patients were two times (OR 2.19, p = 0.71) more likely to experience a relapse compared to MPO ANCA+ patients. CONCLUSIONS: This study demonstrates that PR3 ANCA+ patients may be more likely to experience relapse post-transplant. Further investigation of the predictors of vasculitis relapse among AAV patients who are ANCA+ at the time of RTx needs to be pursued.
BACKGROUND: Renal transplantation (RTx) is the modality of choice for ESRD due to ANCA associated vasculitis (AAV). The significance of ANCA positivity (ANCA+) at the time of RTx on recurrent disease is controversial. METHODS: We evaluated clinical outcomes and predictors of vasculitis relapse in sixteen transplanted AAV patients who were ANCA+ at RTx at a single University Medical Center. Allograft function, vasculitis relapse, and predictors of vasculitis relapse were assessed using descriptive statistics and logistic regression analysis. RESULTS: Our cohort had a median age of 64 years, 88 % Caucasians, 63 % males, 50 % PR3+. All patients were in remission at the time of RTx. Twelve received induction therapy and all were on mycophenolate mofetil, prednisone and tacrolimus. The mean (SD) serum creatinine was 1.2 (0.3) mg/dl at 1 year and 1.8 (1.7) mg/dl at last follow up. Six developed vasculitis relapse at post-transplant. All relapses were treated with escalation in immunosuppression. One non-compliant patient suffered graft loss while the remaining patients achieved remission. In adjusted logistic regression analysis, PR3 ANCA+ patients were two times (OR 2.19, p = 0.71) more likely to experience a relapse compared to MPO ANCA+ patients. CONCLUSIONS: This study demonstrates that PR3 ANCA+ patients may be more likely to experience relapse post-transplant. Further investigation of the predictors of vasculitis relapse among AAV patients who are ANCA+ at the time of RTx needs to be pursued.
Entities:
Keywords:
ANCA vasculitis; Glomerulonephritis; Kidney transplantation; Outcomes; Recurrence; Rituximab
Authors: Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel Journal: Rheumatology (Oxford) Date: 2011-10-29 Impact factor: 7.580
Authors: Michael Walsh; Oliver Flossmann; Annelies Berden; Kerstin Westman; Peter Höglund; Coen Stegeman; David Jayne Journal: Arthritis Rheum Date: 2012-02
Authors: Robert A F de Lind van Wijngaarden; Herbert A Hauer; Ron Wolterbeek; David R W Jayne; Gill Gaskin; Niels Rasmussen; Laure-Hélène Noël; Franco Ferrario; Rüdiger Waldherr; E Christiaan Hagen; Jan A Bruijn; Ingeborg M Bajema Journal: J Am Soc Nephrol Date: 2006-07-06 Impact factor: 10.121
Authors: Laurence Beck; Andrew S Bomback; Michael J Choi; Larry B Holzman; Carol Langford; Laura H Mariani; Michael J Somers; Howard Trachtman; Meryl Waldman Journal: Am J Kidney Dis Date: 2013-07-18 Impact factor: 8.860
Authors: Hyeok Chan Kwon; Minyoung Kevin Kim; Jason Jungsik Song; Yong Beom Park; Sang Won Lee Journal: Yonsei Med J Date: 2020-08 Impact factor: 2.759